Nathan is the Vice President of Technical Operations, joining UNITY in 2017, and leads the process development and manufacturing activities for Unity’s pipeline. Prior to UNITY, Nathan worked at Global Blood Therapeutics from 2014-2017 where he established the Chemistry, Manufacturing and Controls (CMC) group and managed all CMC aspects through Phase 1 for GBT’s small molecule therapy, GBT440. He later focused on late-stage GBT440 drug substance process optimization and control strategies as well as managing IND-enabling CMC activities in support of GBT’s pipeline.
From 2003 to 2014, Nathan worked at Exelixis as a process chemist and was closely involved in the drug substance NDA/MAA activities for the now commercial oncology therapy, Cometriq. Nathan also managed the early CMC development for Cotellic, a marketed therapy developed between Exelixis and Roche/Genentech. Prior to Exelixis, Nathan worked as a process chemist in the agrochemical industry.
Nathan earned his BS in chemistry at DePauw University, a Ph.D. in organic chemistry at Colorado State University, and performed post-doctoral research in synthetic organic chemistry at the University of Colorado, Boulder.